A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma - Full Text View

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

This study has been completed.

Sponsored by:	Teva Pharmaceutical Industries
Information provided by:	Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:	NCT00203008

Purpose

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

Condition

Parkinsons Disease
Malignant Melanoma

Genetics Home Reference related topics:

Parkinson disease

MedlinePlus related topics:

Melanoma Parkinson's Disease

U.S. FDA Resources

Study Type:	Observational
Study Design:	Other

Official Title:	A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients

Further study details as provided by Teva Pharmaceutical Industries:

Estimated Enrollment:	2106
Study Start Date:	January 2003
Study Completion Date:	September 2003

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Confirmed diagnosis Parkinson's disease Patient able and willing to give informed consent Patient must not be taking any investigational drug at the time of enrollment

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00203008

Locations


United States, California
	The Parkinson's & Movement Disorder Institute
	Fountain Valley, California, United States, 92708

United States, Georgia
	Emory University
	Atlanta, Georgia, United States, 30329

United States, Nebraska
	Creighton University
	Omaha, Nebraska, United States, 68131

United States, New York
	Long Island Jewish Medical Center
	New Hyde Park, New York, United States, 11040

United States, Pennsylvania
	Pennsylvania Hospital
	Philadelphia, Pennsylvania, United States, 19107

United States, Rhode Island
	Memorial Hospital of Rhode Island
	Pawtucket, Rhode Island, United States, 02860

United States, Virginia
	University of Virginia Health System
	Charlottesville, Virginia, United States, 22908

Canada, Quebec
	CHUM-Hotel-Dieu
	Montreal, Quebec, Canada, H2w1T8

Sponsors and Collaborators

Teva Pharmaceutical Industries

Investigators


Study Director:	Bruce Schwartz, Ph.D.	Teva Neuroscience, Inc.

More Information

Responsible Party:	Teva Neuroscience ( J. Michael Nicholas, PhD, Sr. Director )
Study ID Numbers:	EP002
First Received:	September 13, 2005
Last Updated:	December 11, 2007
ClinicalTrials.gov Identifier:	NCT00203008
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Ganglion Cysts

Basal Ganglia Diseases

Central Nervous System Diseases

Neurodegenerative Diseases

Brain Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Parkinson Disease

Movement Disorders

Neoplasms, Germ Cell and Embryonal

Nevus, Pigmented

Neuroepithelioma

Nevus

Parkinsonian Disorders

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Histologic Type

Nervous System Diseases

Neoplasms, Nerve Tissue

Nevi and Melanomas

ClinicalTrials.gov processed this record on September 05, 2008